Global Peptide Cancer Vaccine Market and Clinical Trials Insight 2026

  • No. of Pages: 200
  • Publish Date: April-2021
  • Category: Pharmaceutical and Healthcare
Electronic Access - Single User License
$2400
CD-ROM Mail Delivery
$3300
Hard Copy Mail Delivery
$3600
Electronic Access - Multi-User License
$4800

“Global Peptide Cancer Vaccine Market and Clinical Trials Insight 2026” Report Highlights:

 

  • Global Peptide Cancer Vaccine Market Trends Insight
  • Global Peptide Cancer Drugs Market Opportunity: >USD 20 Billion
  • Global Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication and Phase
  • Number Of Peptide Vaccines In Pipeline: >90
  • Application of Peptide Cancer Vaccine Against Major Cancer

 

The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer.

 

The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers.

 

Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. , GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries.

 

Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells.

 

Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the RandD sector.

 

As per “Global Peptide Cancer Vaccine Market and Clinical Trials Insight 2026” report findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry.

 

Need custom market research solution? We can help you with that too.